Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Humanigen claims a Covid-19 win with lenzilumab
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Roche and Vir add to the conflicting Covid-19 data
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
Gilead challenges Viiv in heavily treated HIV
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
